ADVANCES IN PRECLINICAL MODELS FOR SCREENING ANTIPSYCHOTIC ACTIVITY: A COMPREHENSIVE REVIEW

Efficiently developing effective antipsychotic drugs is one of the most daunting challenges in modern psychiatric drug discovery. Although there has been extensive research in the past 70 years since chlorpromazine was first used to treat schizophrenia, the therapeutic strategies that are available today are still largely dependent on the manipulation of dopamine D₂ receptors, which provides only partial relief of symptoms and has significant side effects. This comprehensive review critically discusses the development, present status and future directions of the preclinical models that are used to test antipsychotic drug properties. We critically review classic pharmacologic paradigms, as well as genetic and neurodevelopmental research strategies, human stem cell-based technology, computational strategies, and novel technologies that are changing the landscape of the field. This enduring disconnect between the drug discovery and drug development preclinical and clinical phases is reviewed in terms of model validity, model predictive value and strategic changes to improve drug development pipelines. We envision a third-generation combination of recent advances in optogenetics, 3D brain organoids, machine learning algorithms, and integration of multi-omics to produce a truly novel approach to antipsychotic screening that could end the therapeutic stagnation associated with schizophrenia.

• McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020; 19(1): 15–33.
• Howes OD, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015; 29(2): 97–115.
• Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016; 388(10039): 86–97.
• Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022; 399: 473–486.
• Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-cognitive model. Lancet. 2014; 383: 1677–1687. 
• Kahn RS, Sommer IE, Murray RM, et al. Schizophrenia. Nat Rev Dis Primers. 2015; 1: 15067. 
• Insel TR. Rethinking schizophrenia. Nature. 2010; 468: 187–193. 
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, "just the facts". Schizophr Res. 2009; 110: 1–23. 
• Stahl SM. Beyond the dopamine hypothesis of schizophrenia. CNS Spectrums. 2018; 23: 187–191. 
• Correll CU, Schooler NR. Negative symptoms in schizophrenia. J Clin Psychiatry. 2020; 81(2): MS19037AH5C. 
• Arciniegas DB. Psychosis. Continuum. 2015; 21: 715–736. 
• van Os J, Kapur S. Schizophrenia. Lancet. 2009; 374: 635–645. 
• Kapur S. Psychosis as a state of aberrant salience. Am J Psychiatry. 2003; 160: 13–23. 
• Coyle JT. NMDA receptor and schizophrenia. Harv Rev Psychiatry. 2006; 14: 303–309. 
• Coyle JT. Glutamate and schizophrenia. Cell Mol Neurobiol. 2006; 26: 365–384.
• Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis. Neuron. 2012; 76: 122–137. 
• Javitt DC. Glutamate in schizophrenia. Neuron. 2007; 54: 653–656. 
• Lisman JE, Coyle JT, Green RW, et al. Circuit-based framework for schizophrenia. Trends Neurosci. 2008; 31: 234–242. 
• Grace AA. Dopamine system dysregulation. Nat Rev Neurosci. 2016; 17: 524–532.
• Grace AA. Dysregulation of the dopamine system. Nat Rev Neurosci. 2012; 13: 269–281. 
• Carlsson A. The current status of the dopamine hypothesis. Neuropsychopharmacology. 1988; 1: 179–186. 
• Abi-Dargham A. Dopamine dysfunction in schizophrenia. Biol Psychiatry. 2004; 55: 239–241. 
• Weinberger DR. Implications of normal brain development. Arch Gen Psychiatry. 1987; 44:          660–669. 
• Weinberger DR, Harrison PJ. Schizophrenia. 3rd ed. Wiley-Blackwell; 2011. 
• Fatemi SH, Folsom TD. The neurodevelopmental hypothesis. Schizophr Bull. 2009; 35: 528–548. 
• Meyer U. Prenatal immune activation. Nat Rev Neurosci. 2014; 15: 698–711.
• Brown AS, Patterson PH. Maternal infection and schizophrenia. Schizophr Bull. 2011; 37: 284–290. 
• Miller BJ, Goldsmith DR. Inflammation in schizophrenia. Psychiatr Clin North Am. 2019; 42: 13–25. 
• Upthegrove R, Khandaker GM. Cytokines in psychosis. Biol Psychiatry. 2020; 87: 75–87. 
• Müller N. Inflammation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2018; 80: 210–216. 
• Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress. Biol Psychiatry. 2013; 74: 400–409. 
• Yao JK, Keshavan MS. Oxidative stress in schizophrenia. Antioxid Redox Signal. 2011; 15: 2011–2035. 
• Do KQ, Cuenod M. Redox dysregulation. Curr Opin Neurobiol. 2013; 23: 427–435.
• Berk M, et al. Pathways underlying neuroprogression. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35: 804–817. 
• Khandaker GM, Dantzer R. Inflammation and schizophrenia. Lancet Psychiatry. 2015; 2: 258–270. 
• Cannon TD. How schizophrenia develops. Trends Cogn Sci. 2015; 19: 744–756.
• Sullivan PF, Kendler KS, Neale MC. Genetic epidemiology. Arch Gen Psychiatry. 2003; 60: 1187–1192. 
• Ripke S, et al. Biological insights from 108 schizophrenia loci. Nature. 2014; 511: 421–427. 
• Hilker R, et al. Heritability of schizophrenia. Biol Psychiatry. 2018; 83: 492–498. 
• Lewis DA, Sweet RA. Schizophrenia from a neural circuitry perspective. Neuron. 2009; 62: 139–149. 
• Lewis DA. Cortical circuitry and cognitive dysfunction. Neuron. 2012; 75: 767–779. 
• Heckers S, Konradi C. GABAergic mechanisms. Schizophr Bull. 2015; 41: 1093–1099.
• Benes FM. GABA neurons in schizophrenia. Brain Res Rev. 2010; 31: 1–10. 
• Meltzer HY. Serotonergic mechanisms. Clin Neurosci. 1999; 6: 18–22. 
• Meltzer HY, Massey BW. Serotonin receptors and antipsychotics. Curr Opin Pharmacol. 2011; 11:    59–67. 
• Lieberman JA, et al. Effectiveness of antipsychotic drugs. N Engl J Med. 2005; 353: 1209–1223. 
• Leucht S, et al. Comparative efficacy of antipsychotics. Lancet. 2013; 382: 951–962. 
• Leucht S, et al. Sixty years of antipsychotic drug research. Lancet. 2017; 389: 2063–2071. 
• Keepers GA, et al. APA Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 2020; 177: 868–872. 
• World Health Organization. Schizophrenia Fact Sheet. Geneva: WHO; 2022.